Stablecoin Development (SDEV) vs Tiziana Life Sciences (TLSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tiziana Life Sciences (TLSA) has outperformed Stablecoin Development (SDEV) over the past year, losing 49.3% versus a loss of 55.9%. Over five years, TLSA leads with a -27.2% price change compared with -99.9% for SDEV. Tiziana Life Sciences is the larger company by market cap ($143.8 million vs $103.0 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SDEV | TLSA |
|---|---|---|
| Share price | $1.99 | $1.13 |
| Market cap | $102.99M | $143.80M |
| 1-day change | -28.42% | +2.73% |
| YTD return | -90.14% | -26.17% |
| 1-year return | -55.87% | -49.31% |
| 5-year return | -99.92% | -27.15% |
| EPS (TTM) | $-21.13 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $99.75 | $2.30 |
| 52-week low | $0.78 | $0.76 |
| Distance from 52-week high | -98.01% | -50.87% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +606.19% |
| Average volume | 11.42M | 717.23K |
| Shares outstanding | 51.75M | 127.26M |
| Employees | 2 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
SDEV vs TLSA FAQ
Which is bigger, Stablecoin Development or Tiziana Life Sciences?
Tiziana Life Sciences (TLSA) is larger, with a market capitalization of $143.80M compared with $102.99M for Stablecoin Development (SDEV).
Which stock has performed better over the past year, SDEV or TLSA?
TLSA returned -49.31% over the past 12 months, compared with -55.87% for SDEV (price return, excluding dividends). Past performance does not predict future results.
Are Stablecoin Development and Tiziana Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.